Tag: Correvio

Correvio Announces Presentation Of Brinavess® Data At The American College Of Cardiology 2019 Annual Meeting

VANCOUVER, March 20, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced the presentation of new Brinavess® (vernakalant hydrochloride, IV) data at the American College of Cardiology 2019 Annual Meeting taking place March 16-18, 2019, in New Orleans.  This poster presentation highlights reduced […]

Correvio Reports Fourth Quarter and Full Year 2018 Financial Results

Company on Track to Resubmit Brinavess NDA in Q2 2019 Mark H.N. Corrigan, MD to Commence CEO Duties on March 14, 2019 Management to Host Conference Call and Webcast Today, March 13, 2019 at 8:00 a.m. Eastern (5:00 a.m. Pacific) NASDAQ: CORV  TSX: CORV VANCOUVER, March 13, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical […]

Correvio Announces Presentation Of Brinavess Data At Belgian Society Of Cardiology 2019 Annual Congress

VANCOUVER, Feb. 7, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced the presentation of clinical data highlighting the low  rate of hospitalization in patients treated with Brinavess® (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of recent onset atrial […]

Correvio Provides Update On At The Market Offering

VANCOUVER, Jan. 17, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced the completion of sales of all common shares qualified under its ATM Prospectus Supplement (defined below). The Company’s at-the-market sales issuance agreement, dated July 10, 2018, between the Company and […]

Correvio Reports Third Quarter 2018 Financial Results

VANCOUVER, Nov. 6, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV /TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today reported financial results for its third quarter ended September 30, 2018 and commented on recent accomplishments and plans. “The past few months at Correvio have been highlighted by meaningful progress across a number of […]

Correvio Announces Brinavess Eligibility for Patent Extension

VANCOUVER, Oct. 29, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV /TSX: CORV), a specialty pharmaceutical company focused on providing high-quality brands to acute care physicians and patients, today announced that it has received independent regulatory and legal opinions that Brinavess® (vernakalant hydrochloride, IV) may qualify for up to a 5-year patent extension from the U.S. […]

Correvio Announces Intention to Re-File Brinavess® NDA in Second Quarter 2019

VANCOUVER, Oct. 23, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV /TSX: CORV), a specialty pharmaceutical company focused on providing high-quality brands to acute care physicians and patients, today announced that, based on productive pre-NDA discussions with the U.S. Food and Drug Administration (FDA), Correvio plans to resubmit the Brinavess® […]

Correvio Announces EU Survey Data Demonstrating Brinavess Successfully Avoided Hospitalization in 85% of Patients

VANCOUVER, Aug. 16, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today reported positive data highlighting reduced hospitalization in patients treated with Brinavess® (vernakalant hydrochloride, IV), its antiarrhythmic drug for the […]

Correvio Provides U.S. Regulatory Update for BRINAVESS

VANCOUVER, June 11, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today announced that it has received a response from the U.S. Food and Drug Administration (FDA) regarding the regulatory […]

Brinavess Data Receives Top Award For Best Article Published In The Spanish Medical Journal EMERGENCIAS

VANCOUVER, June 6, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the Brinavess®study, titled “Vernakalant in hospital emergency practice: safety and effectiveness,” published by José Carbajosa Dalmau (Alicante, Spain), was awarded first prize for the best work published during […]